Citations

Clear

16280 citation(s) found for "Yu, David".

Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma
Zhang, Weiwei , Sharma, Sunandini , Shah, Roshani , Lone, Waseem , Mehmood, Syed Karman, Chawla, Ravneet Singh, Cappelli, Luca Vincenzo , Heavican‐Foral, Tayla B. , Cannatella, Jeffrey J. , Amador, Catalina, Arif, Aiza, Lim, Soon Thye , Ong, Choon Kiat , Du, Ming‐Qing , Perry, Anamarija M. , Greiner, Timothy C. , Fu, Kai , Trøen, Gunhild, Weinstock, David M. , Laginestra, Antonella, Kim, KyeongJin , Vose, Julie, Weisenburger, Dennis D., Davé, Sandeep S. , Khoury, Joseph D. , Chan, Wing C., Iqbal, Javeed , Bouska, Alyssa , Lone, Waseem G , Cappelli, Luca Vincenzo , Ong, Choon Kiat , Weinstock, David M , Iqbal, Javeed , Holte, Harald , Shah, Rauf A., Soma, Mahfuza Afroz , Yang, Ruimeng , Liu, Xuxiang , Chawla, Ravneet Singh, Fiore, Danilo , Gong, Qiang , Heavican, Tayla B., Smith, Lynette M. , Feldman, Andrew L. , Leval, Laurence de , Vodák, Daniel , Nakken, Sigve , Delabie, Jan , Pileri, Stefano , Pajvani, Utpal B. , Weisenburger, Dennis D. , Horwitz, Steven M. , Inghirami, Giorgio

Mayo Clinic

American Journal of Hematology | June 13, 2025 | Volume: 100 | Issue: 9 | Pages: 1486-1501

10.1002/ajh.27736 | PMID 40510016 Get It

ABSTRACTNodal follicular helper T‐cell (T FH) lymphoma of the angioimmunoblastic (AITL) subtype has a dismal prognosis. Using whole‐exome sequencing (n = 124), transcriptomic (n = 78), and methylation (n = 40) analysis, we identified recurrent mutations in known epigenetic drivers (TET2, DNMT3A, IDH2 R172 ) and novel ones (TET3, KMT2D). TET2, IDH2 R172 , DNMT3A co‐mutated AITLs had poor prognosis (p < 0.0001). Genes regulating T‐cell receptor (TCR) signaling (CD28, PLCG1, VAV1, FYN) or activation (RHOA G17V ) or regulators of the PI3K‐pathway (PIK(3)C members, PTEN, PHLPP1, PHLPP2) were mutated. CD28 mutation/fusion was associated with poor prognosis (p = 0.02). WES of purified, neoplastic T‐cell (CD3+PD1+) demonstrated high concordance with whole tumor biopsies and validated the presence of TET2 and DNMT3A in tumor and non‐lymphoid cells, but other mutations (CD28, RHOA G17V , IDH2 R172 , PLCG1) in neoplastic cells. Integrated DNA‐methylation and mRNA expression analysis revealed epigenetic alterations in genes regulating TCR, cytokines, PI3K‐signaling, and apoptosis. RNA‐seq analysis identified fusion transcripts regulating TCR‐activation (8%), revealed a restricted TCR‐repertoire (α = 87%, β = 72%), and showed the presence of Epstein–Barr virus transcriptome (73%). GEP demonstrated the association of B‐cells or dendritic cells in the tumor milieu with prognosis (p < 0.01). RNA‐seq and WES analysis of 12 AITL‐patient‐derived‐xenografts (PDX) showed that bi‐allelic TET2 and DNMT3A mutations or sub‐clonal mutations (PLCG1, PHLPP2) propagated in sequential passages, and gene signatures related to T FH and T CM (central‐memory) were well‐maintained through passages. Gene expression signatures associated with late PDX passages (3rd–5th) were enriched with proliferation and metabolic reprogramming‐related genes and predicted prognosis in an independent AITL series. Low PHLPP2 mRNA expression predicted poor prognosis (p = 0.05) and engineered PHLPP2 or TET2 loss in CD4+ T‐cells showed enhanced PI(3)K activation, thus uncovering a therapeutic target for clinical trials.
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis
Langford, Carol A. , Friedman, Marcia , Dehghan, Natasha, Gewurz‐Singer, Ora, Koening, Curry L. , Lin, Yih Chang, Moreland, Larry W. , Fifi‐Mah, Aurore , Forbess, Lindsy, Molloy, Eamonn, Yacyshyn, Elaine , McAlear, Carol A. , Burroughs, Cristina , Rhee, Rennie L. , Hajj‐Ali, Rula A. , Cuthbertson, David , Krischer, Jeffrey P. , Friedman, Marcia , Monach, Paul A , Specks, Ulrich , Spiera, Robert F , Yacyshyn, Elaine , Rhee, Rennie L , Jayne, David , Moreland, Larry W , Khalidi, Nader , Springer, Jason , Hellmich, Bernhard , Pagnoux, Christian , Monach, Paul A. , Flossmann, Oliver , Lanyon, Peter , Specks, Ulrich , Spiera, Robert , Jones, Rachel , Warrington, Kenneth J. , Jayne, David , Merkel, Peter A.

Mayo Clinic

Arthritis & Rheumatology | June 12, 2025 | Volume: 77 | Issue: 12 | Pages: 1739-1748

10.1002/art.43272 | PMID 40506793 Get It

Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or equivalent), tapered and discontinued at week 12. Patients already taking methotrexate, azathioprine, mycophenolate, or leflunomide continued this medication at a stable dose. Patients achieving remission remained on their randomized assignment until relapse, early termination, or the common close date 12 months after enrollment of the last patient. Those who had a nonsevere relapse, had nonsevere worsening, or were not in remission by month 6 had the option to receive open‐label abatacept. The primary end point was the rate of treatment failure, defined as relapse, disease worsening, or failure to achieve a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0 or 1 by six months. Results Sixty‐five patients were randomized; 34 received abatacept and 31 received placebo. No statistical difference in the treatment failure rate was found between those who received abatacept and those who received placebo ( P = 0.853). Treatment with abatacept did not demonstrate any statistical difference from placebo in key secondary end points, including time to full remission (BVAS/WG = 0), duration of glucocorticoid‐free remission, relapse severity, prevention of damage, and patient‐reported quality‐of‐life outcomes. There was no difference in the frequency or severity of adverse events between treatment arms, including infection. Conclusion In patients with relapsing, nonsevere GPA, abatacept did not reduce the risk of relapse, severe worsening, or failure to achieve remission.
Associations between temporal lobe cortical NODDI measures and memory function in individuals without clinical dementia
Pillai, Jay J. , Weigand, Stephen D. , Graff‐Radford, Jonathan, Petersen, Ronald C., Jack, Clifford R. , Jack, Clifford R , Pillai, Jay J , Reid, Robert I. , Cogswell, Petrice M. , Vemuri, Prashanthi , Machulda, Mary M. , Knopman, David S. , Graff‐Radford, Jonathan , Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | June 12, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.70384 | PMID 40501140 Get It

Abstract INTRODUCTION Temporal cortical microstructural changes precede cortical atrophy during memory decline. We used neurite orientation dispersion and density imaging (NODDI) to assess such early microstructural change. METHODS Cognitively unimpaired (CU, n = 725) and mildly cognitively impaired (MCI, n = 111) participants from the Mayo Clinic Study of Aging underwent 3T magnetic resonance imaging (MRI), including NODDI and neuropsychological evaluation for calculation of memory z scores. Linear mixed effects modelling assessed the relationship between temporal cortical Neurite Density Index (NDI), Orientation Dispersion Index (ODI), and both baseline and mean annual change in memory z scores. RESULTS NDI was significantly associated with both baseline memory z scores and mean annual change of memory z scores, in the hippocampi and amygdalae. Similar significant associations with ODI were seen in hippocampi, parahippocampal, and fusiform gyri. DISCUSSION Temporal cortical NDI and ODI are early imaging biomarkers of cortical microstructural integrity that may predict memory decline in CU and MCI individuals. Highlights We imaged 836 participants in the Mayo Clinic Study of Aging, who were either cognitively unimpaired (CU) or suffered from mild cognitive impairment (MCI). Neurite orientation dispersion and density imaging (NODDI) is an advanced diffusion magnetic resonance imaging (MRI) technique We found significant associations between new NODDI imaging biomarkers of microstructural integrity and memory function in CU and MCI individuals These relationships were both cross‐sectional in nature and associated with future memory decline Future application of NODDI imaging biomarkers in the setting of anti‐amyloid monoclonal antibody therapy may provide greater insight into memory decline than current cortical atrophy measures.
Cardiometabolic Diseases During Pregnancy and Their Impact on Long-Term Health
David, Paru S., Takalkar, Rujuta , Vegunta, Suneela

Mayo Clinic

Journal of Women's Health | June 12, 2025 | Volume: 34 | Issue: 8 | Pages: 1058-1060

10.1089/jwh.2025.0281 | PMID 40501180 Get It

A Minor Haplotype Variant Determines the Pathogenicity of the p.Ile279Thr Substitution in the Primary Hyperoxaluria Type 1 Gene, AGXT
Ruta, Luana , Cogal, Andrea G. , Pampalone, Gioena, Sas, David J. , Lieske, John C., Rumsby, Gill , Cellini, Barbara , Harris, Peter C. , Harris, Peter C , Lieske, John C.

Mayo Clinic

Journal of Inherited Metabolic Disease | June 11, 2025 | Volume: 48 | Issue: 4 | Pages: No page available

10.1002/jimd.70052 | PMID 40495747 Get It

ABSTRACT Human alanine:glyoxylate aminotransferase (AGT) is a liver peroxisomal enzyme that metabolizes glyoxylate, the oxalate precursor, to glycine. AGT deficiency, due to recessive pathogenic changes in the AGXT gene, results in calcium oxalate accumulation and kidney stones, a condition known as primary hyperoxaluria type 1 (PH1). Most missense variants lead to PH1 by causing AGT misfolding, but their effects manifest differently based on the presence of two polymorphic variants, p.Pro11Leu (p.P11L) and p.Ile340Met (p.I340M), which are usually present in linkage disequilibrium and generate the minor haplotype. While the p.P11L substitution reduces AGT global stability and worsens the effects of pathogenic changes, the p.I340M exerts a stabilizing effect whose role on PH1 pathogenesis has never been elucidated. The p.Ile279Thr (p.I279T) variant is frequent in healthy populations (0.29%), mainly on the major allele, but we present data from six PH1 families (eight patients) suggesting p.I279T as a PH1 pathogenic allele. Interestingly, in these families, p.Thr279 is always associated with p.Leu11 and p.Ile340, thus with a split AGXT haplotype. Analysis of the effects of the p.I279T mutation by in silico predictions, biochemical analyses on purified proteins, and expression in two cellular models of disease ( AGXT1 ‐KO HepG2 and CHO cells) shows that it causes a folding defect that is exacerbated by p.P11L but mitigated by p.I340M, thus explaining why p.Thr279 is pathogenic just on the p.Leu11–p.Ile340 haplotype. These data indicate that genetic screenings for PH1 should document the AGXT haplotype, including its components, to obtain an accurate diagnosis and possible prognostic information.
Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer
Flores, Luis F, Marks, David L. , Vera, Renzo E., Sigafoos, Ashley N. , Tolosa, Ezequiel J. , Almada, Luciana L. , Pease, David R. , Chang, Brian, Tader, Brooke R , LaRue-Nolan, Kayla C. , Matveyenko, Aleksey V. , Wilson, Katherine L. , Dawson, David W. , Fernández-Zapico, Martín E. , Flores, Luis F. , Toruner, Merih Deniz , Chang, Brian, Carr, Ryan M , Graham, Rondell P. , Hagen, Catherine E. , Brown, Matthew , Pin, Christopher L. , Roux, Kyle J.

Mayo Clinic

JCI Insight | June 10, 2025 | Volume: 10 | Issue: 14 | Pages: No page available

10.1172/jci.insight.187799 | PMID 40493403 Get It

For over a century, scientists reported the disruption of normal nuclear shape and size in cancer. These changes have long been used as tools for diagnosis and staging of malignancies. However, to date, the mechanisms underlying these aberrant nuclear phenotypes and their biological significance remain poorly understood. Using a model of pancreatic ductal adenocarcinoma (PDAC), the major histological subtypes of pancreatic cancer, we found that oncogenic mutant KRAS reduces nuclear size. Transcriptomic and protein expression analysis of mutant KRAS–expressing PDAC cells revealed differential levels of several nuclear envelope–associated genes. Further analysis demonstrated the nuclear lamina protein, Emerin (EMD), acted downstream of KRAS to mediate nuclear size reduction in PDAC. Analysis of human PDAC samples showed that increased EMD expression associates with reduced nuclear size. Finally, in vivo genetic depletion of EMD in a mutant KRAS–driven PDAC model resulted in increased nuclear size and a reduced incidence of poorly differentiated PDAC. Thus, our data provide evidence of a potentially novel mechanism underlying nuclear size regulation and its effect in PDAC carcinogenesis.
Establishing a comprehensive artificial intelligence lifecycle framework for laboratory medicine and pathology: A series introduction
Garcia, Christopher A., Reed, Katelyn A. , Day, Patrick L. , Zarella, Mark D. , Hart, Steven N. , Will, Eric J. , Skiffington, John G, Novak, Debra, McClintock, David S. , Lantz, Eric, Day, Patrick , Hart, Steven N , Will, Eric, Rice, Melinda, Novak, Debra A, McClintock, David S , Lantz, Eric, Will, Eric, Rice, Melinda

Mayo Clinic

American Journal of Clinical Pathology | June 10, 2025 | Volume: 164 | Issue: 3 | Pages: 424-437

10.1093/ajcp/aqaf069 | PMID 40650598 Get It

Abstract Objective Despite exponential growth in artificial intelligence (AI) research for laboratory medicine and pathology, a significant gap exists between model development and clinical AI implementation. This article introduces a structured framework, the Clinical AI Readiness Evaluator (CARE), to bridge this gap and support the responsible adoption of AI in clinical laboratory settings. Methods Building upon the Machine Learning Technology Readiness Levels framework, we developed CARE specifically for the clinical laboratory environment by incorporating health care–specific requirements, regulatory considerations, and workflow integration needs. This framework was iteratively refined through practical application across diverse AI use cases within laboratory medicine and pathology. Results The CARE framework provides a systematic approach to AI development and implementation through 8 component workstreams: clinical use case, data, data pipeline, code, clinical user experience, clinical technology infrastructure, clinical orchestration, and regulatory compliance. Unlike generic AI frameworks, CARE distinguishes itself by emphasizing both health care and laboratory workflow integration, regulatory requirements, ethical considerations, and comprehensive validation for clinical contexts. The framework accommodates both internally developed models and commercial AI solutions, providing clear guidance through technology readiness levels and structured review processes. Conclusions The CARE framework addresses the unique challenges of implementing AI in laboratory medicine and pathology by providing a comprehensive roadmap from initial concepts through clinical deployment and maintenance. This article, the first in a series of 4, establishes the foundational AI lifecycle framework, while subsequent articles will explore data documentation, ethical AI considerations, and governance structures. By adopting this structured approach, laboratories can responsibly harness AI’s potential to enhance diagnostic accuracy and operational efficiencies and, ultimately, improve patient care.
Assessing Renal Function Recovery Following Treatment for Post-Robot-Assisted Partial Nephrectomy Renal Artery Pseudoaneurysm
Kahn, Amanda E. , Geldmaker, Laura , Qosja, Neda, Haehn, Daniela A. , Fuqua, Taylor F., Tiwari, Vartika, Hochwald, Alex, Thomas, Colleen S. , Thiel, David D. , Kahn, Amanda , Fuqua, Taylor F.

Mayo Clinic

Journal of Endourology | June 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/end.2025.0046 | PMID 40491414 Get It

Measuring artery diameter in rabbit angiograms for neurovascular disease modeling applications and device testing
Khan, YM , Franklin, J Ford, Bayraktar, Esref Alperen , Oliver, Alexander A , Ding, Yonghong , Lortscher, Sarah, Brinjikji, Waleed , Kadirvel, Ramanathan , Kallmes, David F. , Khan, Yasmine , Franklin, Jack , Bayraktar, Esref Alperen , Oliver, Alexander A , Ding, Yong-Hong , Lortscher, Sarah , Brinjikji, Waleed , Kadirvel, Ram , Kallmes, David F , Cortese, Jonathan

Mayo Clinic

Interventional Neuroradiology | June 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251347398 | PMID 40491341 Get It

Background and purpose New Zealand White Rabbits are a useful preclinical model for neurovascular research. Inducing right common carotid artery aneurysms in New Zealand White Rabbits gives researchers the ability to test neurovascular devices in vivo. This study takes advantage of archived angiograms to obtain vascular measurements of interest for future research in rabbit models. Methods Rabbit angiograms from endovascular studies conducted in-house between 2005 and 2024 were analyzed using ImageJ at points of interest along the thoracic and abdominal aorta. Using scale references, the diameters of various New Zealand White Rabbit (2.5–3.5 kg) arteries were measured for aneurysm models and controls. Anatomic vascular variations were categorized and recorded. Results Measurable artery diameters at 39 points of interest were recorded for 170 female New Zealand White Rabbits. Type 1 vascular anatomy was the most common rabbit aortic arch, characterizing 85% of identifiable rabbit anatomies in this study. Conclusion By making these measurements available, this study simplifies future neurovascular studies, allowing for vasculature to be selected by size depending on the application. Additionally, the study offers insight into the relationship between elastase-induced aneurysms and surrounding vasculature size and draws size comparisons between some key arteries of interest.